Two Phase 3 Trials of Baricitinib for Alopecia Areata

    March 2022 in “ The New England Journal of Medicine ”
    Brett King, Manabu Ohyama, Oh Sang Kwon … Rodney Sinclair
    Studysummary In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on nejm.org →
    Discuss this study in the Community →

    Research cited in this study 21

    1. Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study Journal of The American Academy of Dermatology · 2021
    2. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
    3. ‘You Lose Your Hair, What’s the Big Deal?’ I Was So Embarrassed, I Was So Self-Conscious, I Was So Depressed: A Qualitative Interview Study to Understand the Psychosocial Burden of Alopecia Areata Journal of Patient-Reported Outcomes · 2020
    4. Development of Clinician-Reported Outcome and Patient-Reported Outcome Measures for Eyebrow, Eyelash, and Nail Assessment in Alopecia Areata American Journal of Clinical Dermatology · 2020
    5. The Alopecia Areata Investigator Global Assessment Scale: A Measure for Evaluating Clinically Meaningful Success in Clinical Trials British Journal of Dermatology · 2020
    6. Treatment of Severe Alopecia Areata with Baricitinib JAAD Case Reports · 2019
    7. The Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata: A Systematic Review Dermatologic therapy · 2019
    8. JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2019
    9. Treatment of Alopecia Areata: An Australian Expert Consensus Statement Australasian journal of dermatology · 2018
    10. JAK Inhibitors for Treatment of Alopecia Areata ˜The œjournal of investigative dermatology/Journal of investigative dermatology · 2018
    11. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis Journal of Investigative Dermatology · 2018
    12. Alopecia Areata: Treatment Options and Efficacy Journal of the American Academy of Dermatology · 2017
    13. JAK Inhibitors in Dermatology: The Promise of a New Drug Class Journal of the American Academy of Dermatology · 2017
    14. Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016
    15. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    16. Health-Related Quality of Life Among Patients With Alopecia Areata: A Systematic Review Journal of The American Academy of Dermatology · 2016
    17. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib EBioMedicine · 2015
    18. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    19. S1 Guideline for Diagnostic Evaluation in Androgenetic Alopecia in Men, Women, and Adolescents British Journal of Dermatology · 2010
    20. Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity Nature · 2010
    21. Lymphocytes, Neuropeptides, And Genes Involved In Alopecia Areata Journal of Clinical Investigation · 2007

    Related research 6

    1. Baricitinib Results in Eyebrow and Eyelash Growth in Patients With Alopecia Areata Who Do Not Achieve 20% or Less Scalp Hair Loss Journal of The American Academy of Dermatology · 2022
    2. Sensitive Scalp: An Epidemiologic Study in Patients with Hair Loss Dermatology Reports · 2022
    3. Time to Loss of Response for Dupilumab in Ophiasis-Pattern Alopecia Areata JAAD case reports · 2021
    4. A Clinico-Epidemiological Study of Scalp Hair Loss in Children (0–18 Years) in Kota Region, South-East Rajasthan Indian Journal of Dermatology · 2019
    5. Topical and Intralesional Therapies for Alopecia Areata Dermatologic therapy · 2011
    6. Alopecia Areata: Clinical Presentation, Diagnosis, and Unusual Cases Dermatologic Therapy · 2011